LGVN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

LG

Mkt Cap

$4.5M

Volume

65.46K

Next Earnings

November 3rd

Loading chart

LG

LGVNLongeveron Inc. Common Stock

LGVN

Pay with—

Available Balance0.00

LG

Mkt Cap

$4.8M

Volume

65.46K

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

Longeveron Announces 1-for-10 Reverse Stock SplitLongeveron Inc. (NASDAQ: LGVN) announced a 1-for-10 reverse stock split effective August 26, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The reverse split will reduce outstanding Class A shares from approximately 30.4 million to 3.0 million shares. The company is approaching milestones across four stem cell therapy development programs and appointed Nirav Jhaveri as Chief Financial Officer.GlobeNewswire Inc. · Aug 24, 2026

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated CellsThe longevity biotech market is expanding rapidly, projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034. Multiple companies are advancing cell and gene therapies targeting age-related diseases: Lineage Cell Therapeutics is developing islet therapy for Type 1 diabetes, Ocugen reported 46% lesion reduction in age-related macular degeneration, Vertex is advancing stem cell-derived islet therapy toward regulatory submissions, and Longeveron published positive Phase 2b data for age-related frailty treatment.Benzinga · Apr 10, 2026

A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.Avaí Bio announced it has initiated manufacturing of a Master Cell Bank of genetically modified cells that overexpress the α-Klotho protein, a key anti-aging protein that naturally declines by 50% after age 40. The milestone represents a transition from research to production infrastructure for their Klothonova anti-aging platform using Cell-in-a-Box® encapsulation technology. The cell therapy sector is rapidly expanding, with the global market projected to grow from $10.4 billion to over $45 billion by 2035.Benzinga · Mar 18, 2026

Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind ThemThe global cell therapy market is projected to surpass $8.2 billion in 2026, with CAR T-cell therapy expanding at 18% annually. Several companies are advancing manufacturing milestones and clinical breakthroughs: Avaí Bio initiated Master Cell Bank production for α-Klotho anti-aging therapy; FibroBiologics secured a patent for fibroblast cell therapy for osteoporosis; Fate Therapeutics achieved same-day hospital discharge for off-the-shelf CAR T-cell patients; Mesoblast presented favorable survival data for Ryoncil® in graft-versus-host disease; and Longeveron published Phase 2b results showing stem cell therapy improved physical condition in age-related frailty patients.Benzinga · Mar 3, 2026

Longeveron Announces Closing Of Up To $17.5 Million Public OfferingLongeveron Inc. completed a public offering of 5,882,354 Class A common stock and short-term warrants, raising approximately $5 million, with potential additional proceeds of $12.5 million from warrant exercises. The company plans to use funds for clinical development of laromestrocel targeting various medical conditions.Benzinga · Aug 11, 2025

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual MeetingLongeveron presented positive long-term survival data for its Lomecel-B treatment in patients with Hypoplastic Left Heart Syndrome (HLHS). The data showed 100% 5-year survival and transplant-free rates, outperforming historical data. The findings support the potential of Lomecel-B as an adjunct therapy to improve outcomes for HLHS patients.GlobeNewswire Inc. · Oct 27, 2024

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment ConferenceAnnovis Bio, a late-stage clinical drug platform company, announced that its Founder, President, and CEO, Maria L. Maccecchini, Ph.D., will participate in the upcoming H.C. Wainwright 26th Annual Global Investment Conference, including a company presentation and a panel discussion on non-amyloid approaches in Alzheimer's disease.GlobeNewswire Inc. · Sep 5, 2024

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)Longeveron announced positive results from its Phase 2a CLEAR MIND clinical trial of Lomecel-B in mild Alzheimer's disease, showing improvements in cognitive function, quality of life, and brain volume.GlobeNewswire Inc. · Jul 28, 2024

Longeveron® Announces U.S. FDA Grants Fast Track - GlobeNewswireLongeveron Inc. announced that the U.S. FDA has granted Fast Track designation to its investigational cellular therapy Lomecel-B™ for the treatment of mild Alzheimer's Disease. This designation will expedite the clinical development and regulatory review of Lomecel-B™ for this indication.GlobeNewswire Inc. · Jul 17, 2024

Why WD-40 Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - BenzingaWD-40 Company reported stronger-than-expected Q3 results, leading to a 12.5% jump in its stock price in pre-market trading. Several other stocks also saw significant price movements in the pre-market session.Benzinga · Jul 11, 2024

to start trading

LG

LGVNLongeveron Inc. Common Stock

LGVN

Pay with—

Available Balance0.00

Your PositionYou don't own any LGVN yet.

Related Tickers

Earnings